The week in pharma: action, reaction and insight – week to March 11, 2022
By Barbara Obstoj-Cardwell. Editor
Research developments were significant among last week’s news, with US biotech Gilead Sciences presenting a bullish view on the TROPICS-02 Phase III trial of its cancer drug Trodelvy, but analysts were not that convinced. French drug major Sanofi and its partner Swedish Orphan Biovitrum released strong new Phase III results for their hemophilia A candidate efanesoctocog alfa. And US drug developer Venatorx came out with positive Phase III results for its urinary tract infection combination – cefepime-taniborbactam. Also of note, Voyager Therapeutics has signed a licensing and research deal that could be worth $1.5 billion with Novartis, for the Swiss pharma giant to get rights to its novel capsids focussed on CNS diseases.
Gilead’s TROPICS readout makes investors sweat
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze